Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Outcome
% Chance
Outcome
%Chance
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
By placing order, you agree to Terms & Conditions
Resolution Criteria
This market resolves to Yes if, on or before December 31, 2030, a drug primarily designed using artificial intelligence is granted full regulatory approval (i.e., full marketing authorization; emergency use authorizations (EUA), conditional approvals, or expanded access do not count) by one of the following regulatory agencies: FDA (US), EMA (EU centralized authorization), MHRA (UK), PMDA (Japan), or NMPA (China) for human use.
“AI-designed” means that, in official company materials and/or regulatory documentation, the drug is explicitly described as having been primarily designed or discovered using AI, where AI is credited with either:
- generating the initial lead molecular structure (or de novo scaffold) that became the approved active ingredient, or
- identifying the biological target or binding hypothesis that the approved drug acts on.
Subsequent human-led optimization and testing does not disqualify the drug.
At least one credible report or official announcement of such an approval by 2030 is required for a Yes resolution. If no such drug is approved by then, the market resolves to No.
News
FDA in Flux — May 2026 Newsletter
The FDA is pursuing real-time clinical trials (RTCTs) and AI-enabled data analytics to shorten drug and biologic development timelines, piloting both early and late-stage RTCT programs intended to enable faster regulatory decisions and continuous trials, with implications for biopharma financing and the need for new trial contracts, monitoring, and data-analysis methods.
Edison Scientific announces partnership with Incyte to deploy Kosmos AI agent across full drug development pipeline from molecular design through FDA approval · Digg
Edison Scientific and Incyte are partnering to deploy Kosmos AI across the full drug development pipeline—from molecular design to FDA approval—claiming it can compress months of work into weeks by coordinating hundreds of agents around a shared, live whiteboard, with fully verifiable outputs and potential for accelerated, cross-domain scientific discovery.
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC⢠Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma announced a favorable FDA Type C meeting outcome for the HARMONIC Phase 2 trial of LP-300 in never-smokers with advanced NSCLC, with no objections to proposed protocol amendments, a plan to enroll future HARMONIC trials focusing on EGFR exon 21 L858R mutations, and an increase of treatment cycles from six to eight.
By: Lantern Pharma Inc. via Business Wire25. Lila Sciences
Lila Sciences, founded in 2023 by Flagship Pioneering and led by CEO Geoffrey von Maltzahn, is building an AI-driven “scientific superintelligence platform” plus AI-powered automated robotic labs to hypothesis, design, and run experiments in real time, with proof of concept in antibodies and carbon capture, backed by a $550 million funding total (including a $350 million Series A at a $1.3B+ valuation) and plans for large-scale facilities near Boston and expansions to San Francisco and London.
Brad Quick33. Iambic
Iambic, a San Diego biotech startup founded in 2020 by Tom Miller and Fred Manby, is highlighted in CNBC’s 2026 Disruptor 50 for proving AI-driven drug discovery at scale, with IAM1363 showing tumor-fighting promise and rapid progression from discovery to clinical trial in two years, plus a recent oversubscribed $100M+ funding round and a multiyear, up to $1.7B deal with Takeda to access its platforms, as it expands beyond cancer into GI and neurological programs.
Brad QuickTandemAI and Mila Announce Research Partnership to Advance AI-Driven Drug Discovery and World Models | Mila
TandemAI and Mila announced a partnership to accelerate AI-driven drug discovery by integrating TandemAI’s generative AI, physics-based modeling, and wet-lab capabilities with Mila’s deep learning expertise, exploring world models for molecular science while committing to open, responsible AI and collaborative knowledge sharing.
Genedata Introduces AI-Native CMC Platform to Accelerate Drug Development and Manufacturing
Genedata unveiled Vico, an AI-native CMC platform built with top biopharma partners to accelerate drug development and manufacturing through data-driven experimentation, AI-assisted DoE and PAT, real-time quality monitoring, and strong data governance, with recognition from Bio-IT World and potential to recoup losses and reduce trial-supply delays.
PR Newswire Tue, May 19, 2026 at 9:30 AM GMT-3 5 min readYour privacy choices
This page outlines Yahoo’s privacy and cookie practices, explaining that by default cookies and personal data may be used for analytics, advertising, and feature security, with options to Accept all, Reject all, or customize privacy settings, and the ability to withdraw consent anytime via privacy settings or the privacy dashboard.
Zacks Equity Research Tue, May 19, 2026 at 10:27 AM GMT-4 4 min readBayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
Bayer’s NDA for asundexian, a once-daily Factor XIa inhibitor for preventing ischemic stroke after non-cardioembolic stroke or high-risk TIA, has been granted FDA Priority Review (six-month timeline) based on Phase III OCEANIC-STROKE results showing a 26% reduction in ischemic stroke with no increase in major bleeding, with simultaneous global regulatory activity including Japan and China.
AInvestNew data boosts our confidence in Lilly's obesity pill. Plus, Google's new AI
New data strengthen confidence in Eli Lilly’s obesity pill, while Google unveils a new AI initiative.
Jeff Marks,Paulina Likos